Table 1.
Baseline characteristics.
| Characteristic | Imatinib + BSC (n = 14) |
BSC alone (n = 12) |
P value† |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 54.5 (48–7) | 62.5 (41–73) | — |
| Sex | |||
| Male | 8 | 8 | 0.701 |
| Female | 6 | 4 | |
| ECOG PS | |||
| 1 | 8 | 4 | 0.220 |
| 2 | 6 | 5 | |
| 3 | 0 | 1 | |
| 4 | 0 | 2 | |
| Change in PS* | |||
| Better | 1 | 0 | 0.003 |
| Worse | 1 | 8 | |
| No change | 12 | 4 | |
| Primary site of cancer | |||
| Stomach | 5 | 3 | 0.913 |
| Small intestine | 7 | 7 | |
| Rectum | 1 | 1 | |
| Other | 1 | 1 | |
| Metastatic sites | |||
| Liver | 5 | 8 | 0.728 |
| Peritoneum | 9 | 9 | |
| Other | 3 | 2 | |
| Duration of initial treatment with imatinib, months | |||
| Median (range) | 41 (20–79) | 19.5 (1–49) | — |
| Best response to initial treatment with imatinib | |||
| CR | 3 | 4 | 0.351 |
| PR | 3 | 2 | |
| SD | 1 | 2 | |
| PD | 3 | 4 | |
| NE | 4 | 0 | |
| Reason for cessation of initial imatinib treatment | |||
| Resistance | 14 | 11 | 0.462 |
| Intolerance | 0 | 1 | |
| Duration of sunitinib therapy, months | |||
| Median (range) | 7.5 (3–17) | 6 (1–34) | — |
BSC: best supportive care; ECOG PS: Eastern Cooperative Oncology Group Performance Status; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluable.
*Compared with presunitinib status.
†Fisher's exact test.